189954-13-0

Basic information

• Product Name: 2(5H)-Furanone, 3-(3,4-difluorophenoxy)-5,5-dimethyl-4-[4-(methylsulfonyl)phenyl]-
• CAS NO: 189954-13-0
• Molecular Formula: C19H16F2O5S
• Molecular Weight: 394.396
• Mol File: 189954-13-0.mol
• Article Data: 9

Chemical Properties

• CAS DataBase Reference: 2(5H)-Furanone, 3-(3,4-difluorophenoxy)-5,5-dimethyl-4-[4-(methylsulfonyl)phenyl]-(CAS DataBase Reference)
• NIST Chemistry Reference: 2(5H)-Furanone, 3-(3,4-difluorophenoxy)-5,5-dimethyl-4-[4-(methylsulfonyl)phenyl]-(189954-13-0)
• EPA Substance Registry System: 2(5H)-Furanone, 3-(3,4-difluorophenoxy)-5,5-dimethyl-4-[4-(methylsulfonyl)phenyl]-(189954-13-0)

Safety Data

• Hazardous Substances Data: 189954-13-0(Hazardous Substances Data)

Upstream product

• 100-68-5 methyl-phenyl-thioether 
• 370-58-1 2-(3,4-difluorophenoxy)acetic acid 
• 180048-73-1 2-hydroxy-2-methyl-1-(4-(methylsulfonyl)-phenyl)propan-1-one 
• 71867-98-6 2-hydroxy-2-methyl-1-(4-(methylthio)phenyl)-propan-1-one 
• 53207-58-2 2-methyl-1-(4-(methylthio)phenyl)-propan-1-one 

Downstream Products

• 189954-73-2 (5R)-3-(3,4-Difluorophenoxy)-5-ethyl-5-methyl-4-(4-methylsulfonyl)phenyl-5H-furan-2-one 
• 189955-46-2 3-(3-Chloro-4-methoxyphenoxy)-5,5-dimethyl-4-(4-methylsulfonyl)-phenyl-5H-furan-2-one 
• 189955-48-4 (5R)-3-(3-chloro-4-methoxyphenoxy)-5-ethyl-5-methyl-4-(4-methylsulfonyl) phenyl-5H-furan-2-one 
• 189955-50-8 (5R)-3-(4-Chlorophenoxy)-5-(2,2,2-trifluoroethyl)-5-methyl-4-(4-methylsulfonyl)phenyl-5H-furan-2-one 
• 189955-52-0 (5R)-3-(4-Bromophenoxy)-5-(2, 2, 2-trifluoroethyl)-5-methyl-4-(4 methylsulfonyl)phenyl-5H-furan-2-one 
• 190966-14-4 5,5-Dimethyl-3-(3,4-difluorophenoxy)-2-hydroxy-4-(4-(methylsulfonyl)phenyl)-2,5-dihydrofuran 

Relevant articles and documents

Method for the treatment and prevention of cachexia

Cachexia, including anorexia and other forms of weight loss, is a frequent complication of acute and chronic infections, and result from induction of cytokines, prostaglandins, and other inflammatory mediators that are critical for pathogen elimination. The present invention includes methods for the treatment or prevention of cachexic conditions while maintaining the production of factors essential for infection control through the administration of an effective amount of a cyclooxygenase-2 selective inhibiting compound.

Antiangiogenic combination therapy for the treatment of cancer

The present invention provides combinations of a DNA topoisomerase I inhibiting agent and a selective COX-2 inhibiting agent for preventing, treating, and/or reducing the risk of developing a neoplasia disorder in a mammal.

ALKYLATED STYRENES AS PRODRUGS TO COX-2 INHIBITORS

The invention encompasses the novel compound of formula (I) useful in the treatment of cyclooxygenase-2 mediated diseases. The invention also encompasses certain pharmaceutical compositions for treatment of cyclooxygenase-2 mediated diseases comprising compounds of formula (I).